Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield ® ) in Patients with Liver Cirrhosis.

Amit GoelAlka VermaPrachi TiwariHarshita KatiyarAmita AggarwalDheeraj Khetannull MayankRavi V Krishna KishorePankaj KumarThakur Prashant SinghSabreena SheikhManas VaishnavPiyush Pathaknull Shalimar

Published in: Vaccines (2022)

induces high titres of ASAb and NAb in cirrhosis. A higher titre is achieved if two doses are given at an interval of more than six weeks.

Keyphrases

immune response
advanced non small cell lung cancer
dendritic cells
gestational age
toll like receptor
inflammatory response
tyrosine kinase
preterm birth